Stock Research: Lotus Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Lotus Pharmaceutical

TSEC:1795 TW0001795003
60
  • Value
    10
  • Growth
    88
  • Safety
    Safety
    38
  • Combined
    32
  • Sentiment
    98
  • 360° View
    360° View
    60
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Lotus Pharmaceutical Co Ltd is a Taiwan-based company focused on manufacturing and selling generic drugs, including solid preparations like tablets and capsules. The company operates in oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs, and mental disease drugs, and is also involved in drug research, development, clinical testing, and product licensing. Its main markets are Taiwan, South Korea, the United States, China mainland, Japan, Europe, and Southeast Asia. In the last fiscal year, the company had a market cap of $1963 million, profits of $333 million, and revenue of $567 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Lotus Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Lotus Pharmaceutical. The consolidated Growth Rank has a good rank of 88, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 88% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 98, which means that professional investors are more optimistic about the stock than for 98% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 38, which means that the share price of Lotus Pharmaceutical is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 62% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 10, which means that the company has a financing structure that is riskier than those of 90% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
FTSE Taiwan
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
38 38 38 65
Growth
88 80 87 85
Safety
Safety
10 13 18 18
Sentiment
98 100 90 69
360° View
360° View
60 69 70 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
97 93 91 95
Opinions Change
50 50 50 50
Pro Holdings
n/a 100 96 4
Market Pulse
86 100 46 79
Sentiment
98 100 90 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
38 38 38 65
Growth
88 80 87 85
Safety Safety
10 13 18 18
Combined
32 38 42 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
81 74 65 91
Price vs. Earnings (P/E)
30 24 24 69
Price vs. Book (P/B)
25 22 18 47
Dividend Yield
58 67 64 62
Value
38 38 38 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
100 84 82 67
Profit Growth
47 44 69 76
Capital Growth
76 55 51 25
Stock Returns
68 64 71 89
Growth
88 80 87 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
19 11 11 8
Refinancing
18 26 29 43
Liquidity
39 22 39 24
Safety Safety
10 13 18 18

Similar Stocks

Discover high‑ranked alternatives to Lotus Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Hoya

TSE:7741
Country: Japan
Industry: Health Care Supplies
Size: X-Large
Full Stock Analysis

Shionogi

TSE:4507
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Kyocera

TSE:6971
Country: Japan
Industry: Electronic Components
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.